Home » Stocks » CYTK

Cytokinetics, Inc. (CYTK)

Stock Price: $24.84 USD 0.52 (2.14%)
Updated May 13, 2021 2:43 PM EDT - Market open
Market Cap 1.74B
Revenue (ttm) 58.55M
Net Income (ttm) -134.99M
Shares Out 71.20M
EPS (ttm) -2.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 13
Last Price $24.84
Previous Close $24.32
Change ($) 0.52
Change (%) 2.14%
Day's Open 24.42
Day's Range 24.21 - 24.96
Day's Volume 266,528
52-Week Range 14.71 - 30.14

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Secondary Analysis From GALACTIC-HF to be Presented in Late Breaking Clinical Trial Session Secondary Analysis From GALACTIC-HF to be Presented in Late Breaking Clinical Trial Session

2 days ago - GlobeNewsWire

Cytokinetics (CYTK) delivered earnings and revenue surprises of -11.86% and -16.41%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

6 days ago - Zacks Investment Research

Secondary Analysis from GALACTIC-HF  to be Presented in Late Breaking Clinical Trial Session at ACC.21

6 days ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the first site has been activated to enroll patients in REDWOOD-HCM OLE, an o...

1 week ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., May 05, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that its Annual Meeting of Stockholders will be held on Wednesday, May 12, 2021 at...

1 week ago - GlobeNewsWire

Next Cohort to Enroll Patients on Background Therapy of Disopyramide Next Cohort to Enroll Patients on Background Therapy of Disopyramide

1 week ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., May 03, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on April 30, 2021 it granted stock options to purchase an aggregate of 69,800...

1 week ago - GlobeNewsWire

Cytokinetics Inc (NASDAQ: CYTK) revealed in an SEC filing that Astellas Pharma Inc (OTCMKTS: ALPMY) is walking away from a pact to research and develop skeletal sarcomere activators for diseases associa...

Other stocks mentioned: ALPMY
1 week ago - Benzinga

SOUTH SAN FRANCISCO, Calif., April 22, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report first quarter results on May 6, 2021 at 4:00 PM E...

2 weeks ago - GlobeNewsWire

Next-In-Class Cardiac Myosin Inhibitor Optimized for Shallow Exposure Response and Pharmacokinetics to Enable Flexible Dose Titration Next-In-Class Cardiac Myosin Inhibitor Optimized for Shallow Exposur...

1 month ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to part...

1 month ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., April 02, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that data relating to CK-3773274 (CK-274), including data regarding its discover...

1 month ago - GlobeNewsWire

Cytokinetics (CYTK) has moved higher as of late, but there could definitely be trouble on the horizon for this company

1 month ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to pres...

2 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on February 26, 2021 it granted stock options to purchase an aggregate of 9,...

2 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on February 28 it is joining the European Organisation for Rare Diseases (EU...

2 months ago - GlobeNewsWire

Company Plans to Meet with FDA in Q1 to Discuss Results of GALACTIC-HF

2 months ago - GlobeNewsWire

Appointment Adds to Board Expertise in Commercial Development and Market Access as Company Prepares for Further Corporate Development Appointment Adds to Board Expertise in Commercial Development and Ma...

2 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report fourth quarter results on February 25, 2021 at 4:0...

3 months ago - GlobeNewsWire

Total of $100,000 Awarded to Five Organizations to Support Communications and Community Outreach Total of $100,000 Awarded to Five Organizations to Support Communications and Community Outreach

3 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on January 29, 2021 it granted stock options to purchase an aggregate of 13,...

3 months ago - GlobeNewsWire

Company Earns $2.5 Million Milestone Payment from Ji Xing Pharmaceuticals Company Earns $2.5 Million Milestone Payment from Ji Xing Pharmaceuticals

4 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designat...

4 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to parti...

4 months ago - GlobeNewsWire

Company is Planning Regulatory Interactions in 2021 to Discuss Results of GALACTIC-HF and Expects to Evaluate Strategic Options for Co-Commercialization and Licensing Company is Planning Regulatory Inte...

4 months ago - GlobeNewsWire

Additional Data from FORTITUDE-ALS Support Rationale and Design for COURAGE-ALS, A Planned Phase 3 Clinical Trial of Reldesemtiv in Patients with ALS Additional Data from FORTITUDE-ALS Support Rationale...

4 months ago - GlobeNewsWire

Interim Analysis of Data from Cohort 1 Demonstrate Substantial Effects of CK-274 to Reduce LVOT Gradient in Patients with Obstructive Hypertrophic Cardiomyopathy with No Dose Interruptions Due to Left V...

5 months ago - GlobeNewsWire

Supplemental Analyses of Primary Composite Endpoint Further Demonstrate Effect of Omecamtiv Mecarbil In Patie nts with Lower Ejection Fraction

5 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced three poster presentations at the 31st International Symposium on ALS/MND taking ...

5 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on November 30, 2020 it granted stock options to purchase an aggregate of 62...

5 months ago - GlobeNewsWire

Data from Supplemental Analyses to be Shared at Clinical Trials Think Tank Meeting Data from Supplemental Analyses to be Shared at Clinical Trials Think Tank Meeting

5 months ago - GlobeNewsWire

In this article we present the list of Top 10 Healthcare Stocks for the Future. Click to skip ahead and see the  Top 5 Healthcare Stocks for the Future .

Other stocks mentioned: INSM, AUPH, NEO, TPTX
5 months ago - Insider Monkey

SOUTH SAN FRANCISCO, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to partic...

5 months ago - GlobeNewsWire

Amgen (AMGN) will terminate the collaboration with Cytokinetics and transition development and commercialization rights for omecamtiv mecarbil and AMG 594 to the latter.

Other stocks mentioned: AMGN
5 months ago - Zacks Investment Research

Company Committed to Advancing Omecamtiv Mecarbil with Initial Focus on Preparation s for Regulatory Interaction s Following Positive Results of GALACTIC-HF

5 months ago - GlobeNewsWire

TipRanks analyst ranking service pinpoints Wall Street's best-performing stocks, like Amazon and Yelp.

Other stocks mentioned: AMZN, YELP, PDFS
5 months ago - CNBC

Appointment Strengthens Commercial, Market Access and Specialty Sales Expertise as Company Advances Pipeline Toward Potential Commercialization Appointment Strengthens Commercial, Market Access and Spec...

5 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that new findings from analyses of claims data and electronic health records rela...

5 months ago - GlobeNewsWire

New Findings from Studies of Cardiac Myosin Inhibitors in Animal Models of Hypertrophic Cardiomyopathy and Heart Failure with Preserved Ejection Fraction New Findings from Studies of Cardiac Myosin Inhi...

5 months ago - GlobeNewsWire

Trial Met Primary Composite Endpoint of Reduction in Heart Failure Events or Cardiovascular Death; Did Not Meet Secondary Endpoints Including Reduction in Cardiovascular Death

6 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on October 30, 2020 it granted stock options to purchase an aggregate of 2,8...

6 months ago - GlobeNewsWire

Primary Results from GALACTIC-HF to be Presented in Late Breaking Clinical Trial Session

6 months ago - GlobeNewsWire

Cytokinetics, Inc. (CYTK) CEO Robert Blum on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

Cytokinetics (CYTK) delivered earnings and revenue surprises of 91.53% and 997.05%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report third quarter results on November 4, 2020 at 4:00 ...

6 months ago - GlobeNewsWire

Amgen Inc. (NASDAQ:AMGN) and its partner, Cytokinetics Inc. (NASDAQ:CYTK), took a punch to the gut last week when the heart drug they were collaborating on failed to meet expectations. Thousand Oaks, Ca...

Other stocks mentioned: AMGN
7 months ago - GuruFocus

Amgen and Cytokinetics disappointed with key Phase 3, final-stage trial results for a heart treatment that aims to reduce cardiovascular death; sending CYTK crashing and AMGN down hard. The post Amgen, ...

Other stocks mentioned: AMGN
7 months ago - Investors Business Daily

Trial Met Primary Composite Endpoint of Reduction in Cardiovascular Death or Heart Failure Events 

7 months ago - GlobeNewsWire

About CYTK

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a novel fast skeletal muscle troponin activator, wh... [Read more...]

Industry
Biotechnology
IPO Date
Apr 29, 2004
CEO
Robert Blum
Employees
184
Stock Exchange
NASDAQ
Ticker Symbol
CYTK
Full Company Profile

Financial Performance

In 2020, Cytokinetics's revenue was $55.83 million, an increase of 107.79% compared to the previous year's $26.87 million. Losses were -$127.29 million, 4.60% more than in 2019.

Financial Statements

Analyst Forecasts

According to 9 analysts, the average rating for Cytokinetics stock is "Buy." The 12-month stock price forecast is 32.64, which is an increase of 31.40% from the latest price.

Price Target
$32.64
(31.40% upside)
Analyst Consensus: Buy